NASDAQ:CNTX

Context Therapeutics Q2 2025 Earnings Results & Report

Context Therapeutics logo
$0.17 0.00 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.17 +0.00 (+0.96%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Context Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$0.09 versus the -$0.06 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Context Therapeutics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Context Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Context Therapeutics Q2 2025 Earnings FAQ

Context Therapeutics (NASDAQ:CNTX) reported earnings of -$0.09 per share for Q2 2025, missing the consensus estimate of -$0.06. The report was announced on Wednesday, August 6, 2025.

Context Therapeutics Earnings Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells.

Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors.

Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.

View Context Therapeutics Profile